Navigation Links
Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research

EMERYVILLE, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Bionovo, Inc. will present findings on the mechanism of action of its anti-cancer agent BZL101, which is advancing to Phase 1/2 clinical testing for late stage breast cancer at the American Association of Cancer Research (AACR) being held at the Los Angeles Convention Center in Los Angeles, CA, April 14 - 17, 2007.

Bionovo's poster presentation will describe the pathway for cancer cell apoptosis (cell death) induced by BZL101 while leaving normal cells unaffected. As explained by Dr. Emma Shtivelman, Director of Cancer Research at Bionovo, the ability of BZL101 to induce apoptosis is due to attenuation of mitochondrial transmembrane potential (MTP) leading to the release of reactive oxygen species, causing inhibition of glycolysis and ending with induction of oxidative DNA damage.

A paper on BZL101's mechanism of action and unique selective properties based on the company's initial Phase 1 clinical trial was published late last year in the peer-reviewed journal, Breast Cancer Research and Treatment.

"BZL101's mechanism of action and unique selective properties" said Dr. Isaac Cohen, President and CEO of Bionovo, "are a result of some of the biological differences between cancer cells and normal cells. We are hoping that capitalizing on the difference will result in a safe and effective treatment for cancer."

Bionovo, Inc.

Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company has two drugs in clinical testing. MF101 is in Phase 2 for quality of life conditions associated with menopause, and BZL101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancreatic cancer and other menopausal symptoms with a total of 4 drug candidates expected to be in
'"/>




Page: 1 2 3

Related medicine technology :

1. Bionovos MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
(Date:7/31/2015)... , July 31, 2015 Egalet Corporation ... specialty pharmaceutical company focused on developing, manufacturing and ... of its previously announced underwritten public offering of ... public offering price of $11.25 per share. The ... 1,000,000 shares issued upon the exercise in full ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015  Eisai ... Ltd. (Headquarters: Tokyo , President and ... Inc. (Headquarters: San Diego, California , ... HALO") have signed a clinical collaboration agreement to evaluate ... in combination with Halozyme,s investigational drug PEGPH20 (PEGylated recombinant ...
(Date:7/31/2015)... CHICAGO , July 31, 2015 ... Composition Analyzers Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy ... and Hydrostatic Weighing) - Global Analysis & Forecast to ... Market was pegged at $911.1 Million 2014 and is ... at a CAGR of 9.4% from 2014 to 2019. ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
(Date:7/31/2015)... ... 2015 , ... Transfinder, a software company based in Schenectady, N.Y., achieved record ... year-over-year for the first six months ended June 30, 2015 compared with the same ... last year’s record-revenue mark of $10.4 million. , “We know what our customers need ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Mount Sinai Health System will work ... the potential of related, experimental treatments. The collaboration moves into the next phase with ... Care one of five state licenses to produce and dispense medical marijuana. , ...
(Date:7/31/2015)... ... July 31, 2015 , ... Successful Import/Export ... http://www.fdanews.com/importexportprogram , Having FDA-regulated products held at ports costs time, money ... risking containment — or even destruction — of products, an FDA insider shows ...
(Date:7/31/2015)... NY (PRWEB) , ... July 31, 2015 , ... Patients ... disease, according to a study published today in Nature Communications and led by researchers ... in mice, suggests that variations in the gene RTN1 led to greater production of ...
(Date:7/31/2015)... ... ... Down is a reputable source of authentic USA vs. Australia tickets at Ford ... National Team in conjunction with their Victory Tour to celebrate winning the 2015 Women's World ... team was awarded the Golden Ball as the best player of the 2015 Women's World ...
Breaking Medicine News(10 mins):Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2
... the most commonly reported vector-borne disease in the United States, ... has been three decades since the agent of the disease, ... vector it were identified. However, the number of Lyme disease ... in the forthcoming issuue of the Journal of Medical ...
... Reporter , WEDNESDAY, Jan. 4 (HealthDay News) -- Some people ... chemotherapy, and a mutation in the so-called TFAP2E gene may ... Knowing which patients carry the mutation might help ... researchers said. "In our study, we identified a gene ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, Jan. ... and deaths in the United States in recent years are charted ... for cancer went down by 1.8 percent a year in men ... (ACS) reported Wednesday. And from 1990 through 2008, death rates ...
... 2012-PORTLAND, Ore. When patients with diabetes experience interruptions in ... the screening tests and vaccines they need to protect their ... when patients receive free or reduced-cost medical care at federally ... part by the National Institutes of Health and findings published ...
... , WEDNESDAY, Jan. 4 (HealthDay News) -- Remember those ... but you took the plunge and whizzed downward. Next, ... and hanging by your knees at the pinnacle. ... sliding boards, safer plastic climbers and fence-protected platforms are ...
... ANGELES Marianne Gausche-Hill, M.D., and Kate Remick, M.D. ... Institute at Harbor-UCLA Medical Center (LA BioMed) are ... Jan. 6, 2012 that will help assess the pediatric ... the first statewide survey of its kind, this project ...
Cached Medicine News:Health News:How can Lyme disease be prevented and controlled? 2Health News:Gene Mutation Linked to Chemo-Resistant Colon Cancer 2Health News:Cancer Incidence, Death Rates Continue to Drop: Report 2Health News:Cancer Incidence, Death Rates Continue to Drop: Report 3Health News:Kaiser Permanente study finds continuous health coverage essential for patients managing diabetes 2Health News:'Safety-First' Playgrounds Linked to Bored, Inactive Kids: Study 2Health News:'Safety-First' Playgrounds Linked to Bored, Inactive Kids: Study 3Health News:LA BioMed investigators lead first survey to determine hospital EDs' pediatric readiness 2
... duty chair with electrical operation with ... and seat rotation with click stops ... heavy duty chair with electrical operation ... mm and seat rotation with click ...
Keeler Professional Combi Retinoscope with new slimline handle and lithium or dry cell option....
Portable mini halogen light....
The MC-3 allows for simultaneous use of two lamps, with an additional built-in spare....
Medicine Products: